New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:17 EDTINCYIncyte to present data from multiple cancer programs at ASCO meeting
Incyte will present new data from its lead cancer programs focused on onco-inflammation, immuno-oncology and myeloproliferative neoplasms at the 50th Annual Meeting of the American Society of Clinical Oncology from May 30 to June 3. Data to be presented include full results from RECAP, the Phase II trial of ruxolitinib in combination with capecitabine in metastatic pancreatic cancer. Topline results showed an overall survival benefit in a pre-specified subgroup analysis of patients. Also being presented are preliminary findings from a Phase I/II study of Incyte’s IDO1 inhibitor, INCB24360, in combination with ipilimumab in patients with metastatic melanoma, designed to examine potential synergy with other cancer immunotherapies. Full results will be presented from the pivotal Phase III RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera, the first Phase III study to evaluate a JAK inhibitor as a treatment for patients with PV, which met its primary endpoint.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 5, 2015
07:55 EDTINCYIncyte fundamentals and pipeline remain strong, says UBS
Subscribe for More Information
August 4, 2015
07:15 EDTINCYIncyte lowers FY15 Jakafi revenue view to $525M-$565M from $560M-$575M
Lowers FY15 R&D expenses view to $450M-$500M from $475M-$500M. Lowers FY15 selling, general, and administrative expenses view to $180M-$200M from $195M-$210M.
07:12 EDTINCYIncyte reports Q2 EPS 5c, consensus (11c)
Subscribe for More Information
August 3, 2015
08:55 EDTINCYIncyte price target raised to $125 from $115 at Leerink
Leerink raised its price target for Incyte to $125 saying its survey of 49 U.S. hematologists indicated Jakafi has blockbuster potential in polycythemia vera. The firm keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use